Neoadjuvant chemotherapy for muscle-invasive bladder cancer: are we asking the right questions?
George Washington University Medical Center, Washington, DC jaragonching@mfa.gwu.edu.
Jeanny B
JB
Aragon-Ching
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002295:Carcinoma, Transitional Cell / Q000737:chemistry* / Q000188:drug therapy*; D015653:Cystectomy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy / Q000379:methods*; D020011:Protective Agents / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000737:chemistry* / Q000188:drug therapy*
D014408:Biomarkers, Tumor; D020011:Protective Agents; D016179:Granulocyte Colony-Stimulating Factor